Novel Nitro Nitrate Lipid Intermediates that Mediate Nitrosating and Alkylating Reactions
This invention introduces a class of nitro-nitrate-lipid intermediates for addressing cardiovascular diseases. The nitro-nitrate-lipid intermediates act as NO donors, providing vasodilatory effects that can improve blood flow and reduce blood pressure. These compounds can be used in various forms, including free fatty acids and esterified lipids, allowing for versatile applications in different medical conditions. The dual action of nitrosating and alkylating reactions may offer superior therapeutic benefits compared to traditional NO donors like nitroglycerin.
Description
These intermediates, derived from unsaturated fatty acids, exhibit unique vasodilatory properties as nitric oxide (NO) donors. This invention holds promise for addressing cardiovascular diseases (CVDs) and other health conditions linked to poor nutrition, potentially reducing medical costs and improving patient outcomes.Applications
• Cardiovascular• Endocrinology and Metabolic Diseases
• Gastroenterology
• Immunology
• Oncology
Advantages
The nitro-nitrate-lipid intermediates act as NO donors, providing vasodilatory effects that can improve blood flow and reduce blood pressure. These compounds can be used in various forms, including free fatty acids and esterified lipids, allowing for versatile applications in different medical conditions. The dual action of nitrosating and alkylating reactions may offer superior therapeutic benefits compared to traditional NO donors like nitroglycerin. Additionally, by targeting specific pathways, these intermediates may reduce the risk of side effects commonly associated with other cardiovascular treatments. Overall, the unique mechanism of action, broad therapeutic potential, enhanced efficacy, and potential for reduced side effects make this invention a promising advancement in the field of cardiovascular treatment.Invention Readiness
The current state of the technology is at the in vitro stage, with promising preliminary data supporting its potential efficacy. The invention has been supported by significant funding from federal and foundation sources, including the NIH and the RiMED Foundation. The next steps in development include further preclinical testing, validation in animal models, and eventual clinical trials to establish safety and efficacy in humans. This invention represents a significant advancement in the field of cardiovascular treatment and has the potential to make a substantial impact on global health outcomes. By addressing the underlying mechanisms of CVDs and other related conditions, these novel nitro-nitrate-lipid intermediates could pave the way for new, more effective therapies.IP Status
https://patents.google.com/patent/US11491128B2Related Publication(s)
Fazzari, M., Woodcock, S. R., Rowart, P., Ricart, K., Lancaster, J. R., Jr., Patel, R., Vitturi, D. A., Freeman, B. A., & Schopfer, F. J. (2021). Endogenous generation of nitro-fatty acid hybrids having dual nitrate ester (RONO2) and nitroalkene (RNO2) substituents. Redox Biology, 41, 101913. https://doi.org/10.1016/j.redox.2021.101913